Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study

Background: Pain management for cats with degenerative joint disease (DJD) remains a critical unmet need. Recent work has shown promise for a feline-specific anti-nerve growth factor monoclonal antibody (frunevetmab) to deliver safe and effective pain management. Our objectives were to evaluate the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Vet Sci
Autors principals: Gruen, Margaret E., Myers, Jamie A. E., Lascelles, B. Duncan X.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Veterinary Science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8195238/
https://ncbi.nlm.nih.gov/pubmed/34124212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fvets.2021.610028
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars